Abstract
Drug repurposing has been proposed as a strategy to develop new therapies that has fewer risks, lower costs and shorter timelines than developing completely new drugs. However, the potential of this strategy has not been as widely realized as hoped, in part owing to legal and regulatory barriers. Here, we highlight these barriers and consider how they could be overcome.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Repositioning Generic Drugs: Empirical Findings and Policy Implications
IIC - International Review of Intellectual Property and Competition Law Open Access 12 September 2022
-
From GWAS to drug screening: repurposing antipsychotics for glioblastoma
Journal of Translational Medicine Open Access 04 February 2022
-
Repurposing the Pathogen Box compounds for identification of potent anti-malarials against blood stages of Plasmodium falciparum with PfUCHL3 inhibitory activity
Scientific Reports Open Access 18 January 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673–683 (2004).
Grabowski, H. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nat. Rev. Drug Discov. 7, 479–488 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Breckenridge, A., Jacob, R. Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev Drug Discov 18, 1–2 (2019). https://doi.org/10.1038/nrd.2018.92
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.92
This article is cited by
-
From GWAS to drug screening: repurposing antipsychotics for glioblastoma
Journal of Translational Medicine (2022)
-
Repurposing drugs to treat cardiovascular disease in the era of precision medicine
Nature Reviews Cardiology (2022)
-
Repurposing the Pathogen Box compounds for identification of potent anti-malarials against blood stages of Plasmodium falciparum with PfUCHL3 inhibitory activity
Scientific Reports (2022)
-
European patent protection for medical uses of known products and drug repurposing
Nature Biotechnology (2022)
-
Repositioning Generic Drugs: Empirical Findings and Policy Implications
IIC - International Review of Intellectual Property and Competition Law (2022)
